Eye tracker hardware and software for paralyzed users, wearable without the need for external display.
Company Founded Year
Company Number of Employees
Brain Computer Interface (BCI)
Medical devices | Medical equipment
Clinical use (of cognitive, psychological, psychiatric, inc. early diagnosis)
EyeControl is an assistive technology for intensive care units. The device uses pupil movements to enable bi-directional remote communication between ventilated patients and medical staff, thereby improving accuracy of care, freeing up beds and equipment, and limiting contagion by reducing the need for proximity. EyeControl has two target markets: medical facilities for ventilated patients and home care for locked-in individuals.
EyeControl will pilot the medical device at hospitals treating patients with COVID-19, where it can help preserve lines of communication between ventilated patients and nurse stations outside quarantine.
EyeControl is CE marked, FDA listed, and ISO certified. The company concluded a clinical trial in the intensive care unit at the Tel Aviv Sourasky Medical Center and is scheduled to conduct an expanded trial at Emory University Hospital.
In 2019, commercialization of the EyeControl home care device commenced in Israel and the United Kingdom. The device is reimbursed by the Israel Ministry of Health, UK National Health Service, and U.S. Centers for Medicare and Medicaid Services.
Combating Coronavirus Pandemic:
The COVID-19 pandemic caused many medical facilities to reach out to EyeControl. As an innovative communication solution for ventilated patients, the product is urgently needed to enhance accuracy of care, decrease recovery time, and speedup patient turnover, while reducing person to person viral exposure. The EyeControl can effectively improve ICU conditions and lessen Coronavirus transmission, by enabling safe and effective remote communication between ventilated patients and medical staff, via the nurse station; loved ones can also maintain patient contact from outside isolated units.